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The Ringling Bros. Center for Elephant
Conservation (CEC), and the International
Elephant Foundation (IEF) hosted the fourth
Annual Tuberculosis and Elephants Workshop on
November 3-4, 2010 in Florida, USA. Workshop
participants included recognized experts in
infectious disease, specifically tuberculosis
and pharmacology, veterinarians, and elephant
managers. The workshop started with a review
of information from the previous ‘Tuberculosis
and Elephants Workshop’ hosted in 2009 by
the St. Louis Zoo, Ringling CEC, and IEF. The
first three Tb workshops identified priorities for
increasing the understanding of tuberculosis (Tb)
in elephants, and participants engaged in focus
groups to develop specific projects to address
those priorities.
Based on the outcomes of the 2009 Tb workshop,
the goals of this year’s workshop were
identified:
- Elucidate current issues with Tb diagnosis in
elephants
- Elucidate current issues with Tb treatment in
elephants
- Develop proposals to address alternative
Tb treatment issues in culture positive
elephants
- Develop research proposals and identify
potential partners to address alternative Tb
treatment issue for prophylactic treatment of
elephants
Two presentations were given on the topic of
Tb treatment. In the first, Dr. Ellen Wiedner
VMD, DACVIM (Ringling CEC, Florida, USA)
reviewed a survey from 2007 looking at effects
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of Tb treatment on elephants in facilities within
the USA (Wiedner & Schmitt 2007). The survey
identified 17 elephants treated for Tb after
having positive trunk wash cultures. Out of those
animals, 14 experienced serious side effects
that were significant enough to stop treatment.
The Tb treatment side effects were varied and
included lack of appetite, ocular issues, colic,
anemia, weight loss, behavioral changes, and
ventral edema. Some of the side effects even
appear to be permanent (i.e. corneal scarring,
ataxia, sterility).
Participant discussions addressed the fact that
the current Tb treatment outlined in the U.S.
Department of Agriculture (USDA) mandated
“Guidelines for the Control of Tuberculosis
in Elephants” is based on out-of-date human
guidelines from 1994, and that monitoring
blood work for drug-related side effects, as
recommended by these guidelines, does not result
in effective monitoring of possible side effects
in elephants. There are currently no reliable or
validated liver enzyme or liver function tests for
elephants. Contrary to most mammals, elephants
produce bile alcohols, not bile acids, and no
tests exist for bile alcohols. Therefore, using
typical serum biochemical tests in elephants to
document liver toxicity from anti-tuberculosis
drugs is not possible. Additionally, the American
Thoracic Society provided updates in human Tb
treatment recommendations in 2007 in response
to recognition of severe liver toxicity and other
side effects associated with anti-tuberculosis
drugs in humans. These recommendations for
human Tb treatments include: shorter duration,
intermittent dosing, and new drug development.

Based on data collection and literature searched,
there is an urgent need to review current Tb
treatment protocols in elephants to ensure the
health and welfare of Tb culture positive animals
(Wiedner & Schmitt 2009).
Dr. Erica Wilson DVM (Dickerson Park Zoo,
Missouri, USA) presented a case report on an
older Asian female elephant. This female, in her
early 60’s, was healthy and normal, and over the
years her trunk wash cultures had always been
negative. In the course of routine Tb testing, the
new Tb blood tests (Elephant Tb Stat-Pak and
MAPIA) currently required by the USDA as part
of testing for tuberculosis in elephants, indicated
the elephant was reactive on the tests. Based on
the serology results, the elephant was treated
for Tb under the 2008 USDA Tb Guidelines.
However this elephant had severe reactions to
the Tb treatment drugs and subsequently died.
On post-mortem no signs of Tb were found.
This is the second such case in the United States,
and clearly raises significant concerns about the
validity of initiating Tb treatment based only on a
serology test. It also demonstrates an urgent need
for further research about Tb treatment options
for elephants.
Much discussion ensued about the decision by
USDA to mandate blood testing for tuberculosis,
via the Elephant Tb Stat-Pak and MAPIA tests,
for all elephants in the U.S. between March
2010 and March 2011. The results provided by
this testing method require critical review, as the
nature of the testing allows varied interpretation
of the results. Demonstrating that a test can
repeatedly identify a set of pre-selected samples
demonstrates repeatability not validity. In
addition, the MAPIA test is only a confirmatory
test for the Elephant Tb Stat-Pak, and not for
tuberculosis. As a confirmatory test to the
Elephant Tb Stat-Pak, the MAPIA separates the
antibodies detected into individual bands, rather
than one band as used in the Elephant Tb Stat-Pak
test. If reactive, then the Elephant Tb Stat-Pak is
confirmed. If non-reactive, then the Elephant Tb
Stat-Pak is considered a false positive. In a recent
publication (Greenwald et. al. 2009) 54% (12/22)
of Elephant Tb Stat-Pak positive elephants from
a group of 63 animals were determined to be in
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this false positive category (i.e. Elephant Tb StatPak positive, MAPIA negative, and Tb culture
negative).
Furthermore, elephants that have chronic
inflammatory issues may test positive on Elephant
Tb Stat-Pak. This suggests that the serological
tests may be identifying markers of inflammation,
which again demonstrates that these tests are
not specific enough for Tb diagnosis. Currently
ChemBio (manufacturer of the Elephant Tb
Stat-Pak and MAPIA tests) runs the (multiple
antigen) antibody test, and, based on proprietary
criteria, makes a determination confirming or
not confirming the reactive Elephant Tb StatPak results. These results should be verified
independently. The ChemBio Dual Pathway
Platform (DPP) test is currently not available for
use in the United States, but is under review for
licensure. If approved for use in the U.S., it will
replace the MAPIA testing to confirm the Elephant
Tb STAT-PAK test Interestingly, according to a
recent publication (Landolfi et al. 2010) much
of the Tb testing of elephants in Asian range
countries has primarily relied on serology using
the Elephant Tb Stat-Pak and MAPIA tests, and
not on cultures of the Tb organism. Data about
the overall percentage of elephants in Asia with
confirmed culture positive diagnosis of Tb is
still not available. In at least one Asian elephant
range country with a known high burden of
tuberculosis in the human population, no clinical
or pathological signs considered suspicious for
tuberculosis in elephants have been noted to date,
and no diagnosis of Tb in elephants have been
confirmed. (C. Stremme, pers. comm.)
The consensus, from experienced veterinarians
and Tb researchers present at the Tb workshop,
was that prior to relying on Tb serology testing
in elephants, there needs to be further study
of the elephant immune system and general
immunology to better understand how elephants
are affected by Tb.
The last topic addressed during the workshop
was whether there is a potential occupational
health risk for people who work with elephants
to develop tuberculosis. The workshop
participants’ consensus was that there is a need

for scientifically accurate information in order
to have this discussion. A cross sectional study
of people working with elephants is currently
being initiated. This study will compare people
working with elephants with those who work
with other animal species. Tb testing of the
people participating in the study will use a
new interferon gold test. The first question will
simply be to determine if people working with
elephants have a positive or negative Tb test. The
second question will determine if people working
with other animal species have a positive or
negative Tb test. The challenge will be matching
participants with years of working with elephants,
to individuals with years of working with nonelephant species. The Elephant Managers
Association (EMA) has offered to be a resource
to help identify participants for this study.
Interesting facts about tuberculosis include:
- In all species, tuberculosis as an active
infection can only be diagnosed following
isolation of the Tb organism through culture
techniques. Serology testing alone does not
confirm a diagnosis of active Tb.
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- When infected, only 3% of humans develop
clinical Tb.
- The vast majority of people affected with Tb
are not shedding and are not contagious to
others, which may be similar in elephants.
It also appears probable that elephants have
long latent periods in which they are not
infective.
- There are currently no reliable liver function
tests for elephants. Contrary to most
mammals, elephants produce bile alcohols,
not bile acids, and liver function tests are
based on enzymes for bile acid. Therefore,
using these tests in elephants to document
liver toxicity from anti-tuberculosis drugs is
not possible.
- Targeted animal safety studies are needed to
determine the thresholds between Tb drug
efficacy and toxicity in elephants.
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